Investigation into Globus Medical, Inc.
Pomerantz LLP is currently looking into potential claims on behalf of investors in Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Shareholders are encouraged to reach out to Danielle Peyton for further information.
Concerns Regarding Business Practices
This investigation seeks to uncover whether Globus, along with some of its officers and directors, may have participated in securities fraud or engaged in other unlawful business practices. This inquiry is especially crucial for shareholders who might have been impacted by the company's actions.
FDA Warning Letter and Stock Drop
Recently, Globus revealed that it had received a warning letter from the U.S. Food and Drug Administration (FDA) following an inspection of its facilities. This inspection, which occurred earlier this year, uncovered deficiencies in their product complaint procedures related to the ExcelsiusGPS robotic system. These findings have raised alarms among investors.
Effect on Share Price
As a direct consequence of the FDA's warning letter, Globus's stock saw a significant drop, decreasing by $5.73 per share, which translates to a 7.84% decline, closing at $67.32 per share.
Pomerantz LLP: Advocates for Investors
Pomerantz LLP, with a strong presence in major cities such as New York and Chicago, is recognized as a leading firm in corporate, securities, and antitrust class litigation. Founded by the esteemed Abraham L. Pomerantz, a pioneer in securities class actions, the firm is committed to advocating for the rights of those affected by fraud and corporate misconduct.
Proven Track Record
With over 85 years of experience, Pomerantz has achieved numerous multimillion-dollar damages awards for class members, showcasing its dedication to delivering justice for individuals impacted by unethical business practices.
Contact Information for Investors
Investors seeking additional information about this investigation can reach out to Danielle Peyton at Pomerantz LLP. She is available via email or directly at the office to assist with any inquiries related to the case.
Frequently Asked Questions
What led to the investigation of Globus Medical, Inc.?
The investigation was initiated due to potential claims of securities fraud and concerns that arose following an FDA warning letter issued to the company.
What did the FDA find during its inspection of Globus Medical?
The FDA's inspection identified deficiencies in the company's complaint procedures associated with their robotic system, resulting in heightened scrutiny from investors.
What impact did the FDA warning have on Globus Medical's stock price?
After the announcement of the FDA warning letter, Globus Medical’s stock price fell by $5.73 per share, adversely affecting shareholder value.
Who should investors contact for more information?
Investors can reach out to Danielle Peyton at Pomerantz LLP for further details regarding the investigation and any potential claims.
What is Pomerantz LLP's expertise in securities litigation?
Pomerantz LLP has extensive experience in securities and corporate litigation, having achieved numerous successful outcomes for its clients over the years.
